SubHero Banner

Kalydeco® (ivacaftor) – Expanded indication

September 25, 2020 - Vertex announced the FDA approval of Kalydeco (ivacaftor), for treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

Download PDF